Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 2, 2011, Pages 181-187

  Gonzalez, Jeffrey S ^a,b   Batchelder, Abigail W ^a   Psaros, Christina ^b,c   Safren, Steven A ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adherence; compliance; depression; HIV AIDS; meta analysis

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIORAL RESEARCH; CLINICAL FEATURE; DEPRESSION; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SELF REPORT; SEXUAL ORIENTATION; SUBSTANCE ABUSE;

EID: 85027921579     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0B013E31822D490A     Document Type: Review

References (69)

1. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366. (Pubitemid 30182431)
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
3. Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105-110. (Pubitemid 34506694)
4. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000; 23:360-361. (Pubitemid 30327043)
5. Bing EG, Burnam A, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728. (Pubitemid 32717795)
6. Burack JH, Barrett DC, Stall R, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270: 2568-2573. (Pubitemid 23346695)
7. Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279-285. (Pubitemid 27132057)
8. Vedhara K, Nott KH, Bradbeer CS, et al. Greater emotional distress is associated with accelerated CD4+ cell decline in HIV infection. J Psychosom Res. 1997;42:379-390. (Pubitemid 27207841)
9. Ironson G, O'Cleirigh C, Fletcher MA, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005;67:1013-1021. (Pubitemid 43740117)
10. Patterson TL, Shaw WS, Semple SJ, et al. Relationship of psychosocial factors to HIV disease progression. Ann Behav Med. 1996;18:30-39. (Pubitemid 26251392)
11. Page-Shafer K, Delorenze GN, Satariano WA, et al. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol. 1996;6:420-430. (Pubitemid 26372530)
12. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474. (Pubitemid 32221895)
13. Ahdieh-Grant L, Tarwater PM, Schneider MF, et al. Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2005;38:500-503. (Pubitemid 40381561)
14. Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39:1190-1198. (Pubitemid 40169319)
15. Nannis ED, Temoshok LR, Smith M, et al. Perceptions of AZT: implications for adherence to medical regimens. J Appl Behav Res. 1993;1:39-54.
16. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
17. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Revised. Washington, DC: American Psychiatric Association; 1987.
18. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
20. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328. (Pubitemid 40333499)
21. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683-688. (Pubitemid 38393468)
22. Murphy DA, Marelich WD, Hoffman D, et al. Predictors of antiretroviral adherence. AIDS Care. 2004;16:471-484. (Pubitemid 38651064)
23. Pence BW, Ostermann J, Kumar V, et al. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:194-201. (Pubitemid 351172186)
24. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDs. 2005;19:326-334. (Pubitemid 40770656)
25. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45:1377-1385. (Pubitemid 351411918)
26. Turner BJ, Laine C, Cosler L, et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248-257. (Pubitemid 36529041)
27. Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials. 2001;2:146-159. (Pubitemid 32331423)
28. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269. (Pubitemid 26164414)
29. Simoni JM, Frick PA, Lockhart D, et al. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDS. 2002;16:431-439.
30. Wagner JH, Justice AC, Chesney M, et al. Patient-and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001;54(suppl 1):S91-S98. (Pubitemid 34013694)
31. Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS. 2005;19:728-736. (Pubitemid 41705169)
32. Leserman J, Ironson G, O'Cleirigh C, et al. Stressful life events and adherence in HIV. AIDS Patients Care STDS. 2008;22:403-411. (Pubitemid 351733239)
33. Liu H, Longshore D, Williams JK, et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav. 2006;10:279-286.
34. Thrasher AD, Earp JA, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84-93.
35. Gonzalez JS, Penedo FJ, Antoni MH, et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004;23:413-418. (Pubitemid 38880174)
36. Rudy BJ, Murphy DA, Harris DR, et al. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS. 2009;23:185-194.
37. Lipsey MW, Wilson DB. Practical Meta-Analysis. Thousand Oaks, CA: Sage Publications; 2001.
38. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to Meta-Analysis (Statistics in Practice). Chichester, United Kingdom: John Wiley & Sons, Ltd; 2009.
39. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395. (Pubitemid 30431595)
40. Gibbie T, Hay M, Hutchison CW, et al. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sexual Health. 2007;4:227-232. (Pubitemid 350158745)
41. Peterson RA, Brown SP. On the use of beta coefficients in meta-analysis. J Appl Psychol. 2005;90:175-181. (Pubitemid 40176555)
42. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103:1828-1836.
43. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
44. Rosenthal R. Meta-Analytic Procedures for Social Research. Beverly Hills, CA: Sage; 1984.
45. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
46. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment-Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160: 2101-2107. (Pubitemid 30482715)
47. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31: 2398-2403.
48. Cohen J. The cost of dichotomization. Psychol Measures. 1983;7: 249-253.
49. Matt GE, Vazquez C, Campbell WK. Mood-congruent recall of affectively toned stimuli: a meta-analytic review. Clin Psychol Rev. 1992;12: 227-255.
50. Hansen RA, Kim MM, Song L, et al. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43:413-422.
51. Gonzalez JS, Psaros C, Batchelder A, et al. Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. Ann Behav Med. 2011;42:120-126.
52. Gonzalez JS, Safren SA, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care. 2007;30:2222-2227. (Pubitemid 47359018)
53. Zangerle R, Widner B, Quirchmair G, et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol. 2002;104:242-247. (Pubitemid 35191100)
54. Zangerle R, Kurz K, Neurauter G, et al. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun. 2010;24:403-408.
55. Schroecksnadel K, Sarcletti M, Winkler C, et al. Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun. 2008;22:881-889.
56. Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34:46-55. (Pubitemid 47481224)
57. Weaver KE, Llabre MM, Duran RE, et al. A stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART). Health Psychol. 2005;24: 385-392. (Pubitemid 41099139)
58. Tucker JS, Orlando M, Burnam MA, et al. Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychol. 2004;23:363-370. (Pubitemid 38880168)
59. Walkup J, Blank MB, Gonzalez JS, et al. The impact of mental health and substance abuse factors on HIV prevention and treatment. J Acquir Immune Defic Syndr. 2008;47(suppl 1):S15-S19. (Pubitemid 351323596)
60. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008;70:539-545.
61. Vranceanu AM, Safren SA, Lu M, et al. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS. 2008;22:313-321. (Pubitemid 351562964)
62. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1-10.
63. Crepaz N, Passin WF, Herbst JH, et al. Meta-analysis of cognitivebehavioral interventions on HIV-positive persons' mental health and immune functioning. Health Psychol. 2008;27:4-14. (Pubitemid 351217074)
64. Brown JL, Vanable PA. Cognitive-behavioral stress management interventions for persons living with HIV: a review and critique of the literature. Ann Behav Med. 2008;35:26-40.
65. Carrico AW, Antoni MH. Effects of psychological interventions on neuroendocrine hormone regulation and immune status in HIV-positive persons: a review of randomized controlled trials. Psychosom Med. 2008; 70:575-584.
66. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56: 146-150.
67. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. JAMA. 1993;270:2563-2567. (Pubitemid 23346694)
68. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS. 1996;10:1033-1039. (Pubitemid 26252635)
69. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol. 2001;54(suppl 1): S22-S28. (Pubitemid 34019141)